Navigation Links
Savient Pharmaceuticals Reports Second Quarter 2009 Financial Results
Date:8/10/2009

and it is uncertain that we will be able to utilize these net operating losses against future income. The 2008 income tax benefit reflects the tax effects of the carry back of our 2008 net operating losses to the 2006 tax year to recover 2006 income taxes paid.

Use of Non-GAAP Measures

To supplement our consolidated financial statements presented in accordance with GAAP, we use the following measures defined as non-GAAP financial measures by the SEC: non-GAAP net loss and non-GAAP loss per basic and diluted share. The presentation of this financial information is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP. In addition, the non-GAAP financial measures included in this press release may be different from, and therefore not comparable to, similar measures used by other companies. Although certain non-GAAP financial measures used in this release exclude the accounting treatment of valuation adjustments associated with our outstanding warrants to purchase shares of our common stock, these non-GAAP measures should not be relied upon independently.

Our management believes that these non-GAAP financial measures provide meaningful supplemental information regarding our performance by excluding certain expenses and expenditures that may not be indicative of our core business operating results. We believe that both management and investors benefit from referring to these non-GAAP financial measures in assessing our performance and when planning, forecasting and analyzing future periods. These non-GAAP financial measures also facilitate management's internal comparisons to our historical performance and our competitors' operating results. We believe that these non-GAAP measures are useful to investors in allowing for greater transparency with respect to supplemental information used by management in its financial and o
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine news :

1. Savient Pharmaceuticals to Present at the Credit Suisse Phoenix Healthcare Conference on November 13th
2. Savients Board of Directors Forms a Board Committee to Oversee the Regulatory and Pre-Launch Activities for Pegloticase
3. Savient Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference on January 14th
4. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results
5. Savient Pharmaceuticals to Present at The Cowen and Company 29th Annual Healthcare Conference on March 17, 2009
6. Savient Pharmaceuticals Receives Complete Response Letter from U.S. Food and Drug Administration for KRYSTEXXA(TM)
7. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
8. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
9. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... According to ... helpfulness of a doctor is tied directly to the success of a patient who ... a two year period, measured their weight loss over that period, and compared those ...
(Date:8/27/2015)... Montana (PRWEB) , ... August 27, 2015 , ... ... Association, the average annual cost to treat a patient with hemophilia is $175,000. ... in finding a cure and improving treatment. The RMHBDA exists to help raise ...
(Date:8/27/2015)... ... August 27, 2015 , ... According to an article published ... released new guidelines to educate doctors and patients on the best practices for type ... came in 2007, so the new version is taking into account nearly a decade ...
(Date:8/27/2015)... ... August 27, 2015 , ... Allegheny General Hospital (AGH), ... adult-only medical centers in the United States to receive international recognition for an ... Extracorporeal Life Support Organization (ELSO) , an international consortium of healthcare institutions ...
(Date:8/27/2015)... ... 27, 2015 , ... About 10 percent of mothers experienced ... Coast, killing more than 1,800 people, displacing hundreds of thousands and causing widespread ... study. , While most people don’t develop persistent depression after a major disaster ...
Breaking Medicine News(10 mins):Health News:Article on Physician Influence on Weight Loss Highlights the Importance of a Doctor Who Cares, says Dr. Feiz & Associates 2Health News:Avitus Group Encourages Business & Employee Community Involvement; Senior Level Staff Leads Way With Support of Rocky Mountain Hemophilia & Bleeding Disorders Association 2Health News:Avitus Group Encourages Business & Employee Community Involvement; Senior Level Staff Leads Way With Support of Rocky Mountain Hemophilia & Bleeding Disorders Association 3Health News:Avitus Group Encourages Business & Employee Community Involvement; Senior Level Staff Leads Way With Support of Rocky Mountain Hemophilia & Bleeding Disorders Association 4Health News:Article on New Diabetic Care Guidelines Shines Brightly on Weight Loss Surgery, notes Beverly Hills Physicians 2Health News:Article on New Diabetic Care Guidelines Shines Brightly on Weight Loss Surgery, notes Beverly Hills Physicians 3Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 2Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 3Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 4Health News:About 10 Percent of Mothers Experienced Depression Two Years After Hurricane Katrina, New Study Shows 2
... Jan. 14 Speaker Nancy Pelosi spoke on the ... the State Children,s Health Insurance Program (SCHIP) Reauthorization bill, which ... 139. Below are the Speaker,s remarks: "My colleagues, this is ... expect to be a strong bipartisan vote, the House will ...
... 14 The Blue Foundation for a Healthy ... Blue Shield of Florida (BCBSF), has approved $761,000 in ... Florida organizations providing health-related services to in-need Floridians."Around 20 ... executive director of The Blue Foundation for a Healthy ...
... Demonstrates Treatment Success, and Highlights Potential Factors that Affect ... C - NUTLEY, N.J., Jan. 14 Results from ... Latino patients with the hepatitis C virus (HCV), were ... Medicine (NEJM).(1) This Roche study demonstrated that HCV ...
... too costly for some centers, experts say , , ... measure of blood flow to determine where artery-opening ... the X-ray examinations now commonly used, an international ... as "fractional flow reserve" (FFR), is designed for ...
... term and the Obama administration prepares to assume power, the ... recognize the importance of public health as the foundation for ... on the president and Congress to:, ... to health care. APHA urges the administration to ensure ...
... A special series of papers in the peer-reviewed journal ... look at future directions of research on pigment biology. Model ... genetic basis of human skin color and race. The papers, ... Mary Ann Liebert, Inc., and are available online at ...
Cached Medicine News:Health News:Pelosi: SCHIP Vote Brings Us One Step Closer to Providing Health Care for 11 Million Children 2Health News:Pelosi: SCHIP Vote Brings Us One Step Closer to Providing Health Care for 11 Million Children 3Health News:Florida's Uninsured and Underinsured to Benefit from Statewide Grants 2Health News:PEGASYS(R) Proven Effective as Hepatitis C Treatment for Latino Patients, According to Article in The New England Journal of Medicine 2Health News:PEGASYS(R) Proven Effective as Hepatitis C Treatment for Latino Patients, According to Article in The New England Journal of Medicine 3Health News:PEGASYS(R) Proven Effective as Hepatitis C Treatment for Latino Patients, According to Article in The New England Journal of Medicine 4Health News:PEGASYS(R) Proven Effective as Hepatitis C Treatment for Latino Patients, According to Article in The New England Journal of Medicine 5Health News:PEGASYS(R) Proven Effective as Hepatitis C Treatment for Latino Patients, According to Article in The New England Journal of Medicine 6Health News:PEGASYS(R) Proven Effective as Hepatitis C Treatment for Latino Patients, According to Article in The New England Journal of Medicine 7Health News:PEGASYS(R) Proven Effective as Hepatitis C Treatment for Latino Patients, According to Article in The New England Journal of Medicine 8Health News:PEGASYS(R) Proven Effective as Hepatitis C Treatment for Latino Patients, According to Article in The New England Journal of Medicine 9Health News:Blood Flow Measurement Boosts Stent Outcomes 2Health News:Blood Flow Measurement Boosts Stent Outcomes 3Health News:APHA Releases Public Health Priorities for New Congress and Administration 2Health News:Zebrafish Journal Publishes Skin Pigmentation Studies That Shed Light on the Evolution of Race 2Health News:Zebrafish Journal Publishes Skin Pigmentation Studies That Shed Light on the Evolution of Race 3
(Date:8/27/2015)... Aug. 27, 2015   Americord Registry , a ... and placenta tissue banking company, announced today ... e-commerce website. This new website makes the expecting parent,s ... interactive shopping cart and checkout process. Logo ... blood banking websites make this service difficult to purchase ...
(Date:8/27/2015)... 2015 According to a ... titled "Global Market Study on Urinary Catheters: Intermittent ... the urinary catheters market is expected to be valued at ... is anticipated to expand at a CAGR of4.1% ... by 2021. View full report TOC at: ...
(Date:8/27/2015)... Calif. , Aug. 27, 2015  CytomX ... for the treatment of cancer, today announced that ... of the company,s Board of Directors, has been ... immuno-oncology at Eli Lilly and AstraZeneca, and also ... FDA approved checkpoint inhibitor, at Bristol-Myers Squibb and ...
Breaking Medicine Technology:Cord Blood Bank Revolutionizes Process of Online Cord Blood Banking 2Global Urinary Catheters Market Will Reach US$1,755.0 Mn by 2021: Persistence Market Research 2Global Urinary Catheters Market Will Reach US$1,755.0 Mn by 2021: Persistence Market Research 3Global Urinary Catheters Market Will Reach US$1,755.0 Mn by 2021: Persistence Market Research 4Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer 2Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer 3
... 2011 Reportlinker.com announces that a ... in its catalogue: ... Market 2011-2021 ... the commercial prospects for lyophilisation technology? ...
...  Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN ) today ... the 2011 Deutsche Bank BioFEST scheduled for Monday, December ... Eastern Time.  The session may be accessed through the ... Relations page.  An archived version of the presentation will ...
Cached Medicine Technology:Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 2Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 3Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 4Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 5Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 6Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 7Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 8Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 9Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 10Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 11Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 12Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 13Regeneron Announces Presentation Time Change at the 2011 Deutsche Bank BioFEST 2
... (P-ANCA) is for the specific detection ... myeloperoxidase as antigen. No false-positive results ... elastase in the antigen preparation. MPO ... indirect immunofluorescence; only about 10% of ...
... Inc. (DAI) Myeloperoxidase (MPO) Enzyme-Linked Immunosorbent ... and semi-quantitative determination of IgG, A, M ... assay is used to detect antibodies ... of the assay are to be used ...
... is a solid phase two-site enzyme ... direct sandwich technique in which two ... antigenic determinants on the insulin molecule. ... react with peroxidase-conjugated anti-insulin antibodies and ...
Anti-RSV IgM Assay (ELISA)....
Medicine Products: